Suppr超能文献

感染后胆汁酸吸收不良:这是一种长期情况吗?

Postinfective bile acid malabsorption: is this a long-term condition?

机构信息

Department of Gastroenterology, Sandwell General Hospital, West Bromwich, UK.

出版信息

Eur J Gastroenterol Hepatol. 2011 Apr;23(4):308-10. doi: 10.1097/MEG.0b013e3283457ba6.

Abstract

BACKGROUND

Postinfective bile acid malabsorption comprises a group of patients with a history of an episode of acute gastroenteritis triggering chronic diarrhoea. We identified these patients retrospectively from our medical records and assessed their long-term clinical course.

MATERIALS AND METHODS

We examined the records of 135 patients with 75 selenium-homocholic acid taurine results less than 10% (1 week retention).

RESULTS

Twenty-five patients (13 female, 12 male) had a diagnosis of postinfective bile acid malabsorption established after extensive investigations. Cholestyramine was used to treat diarrhoea with a mean frequency of diarrhoea decreasing from 7.8 to 1.9 (P=0.001). The mean cholestyramine dose decreased from 8.2 to 5.4 g/day (P=0.005). Eighteen of 25 (72%) patients had a successful resolution of their diarrhoea by cholestyramine and have continued it to date. The median duration of outpatient follow-up was 1.58 years (range: 1-5 years). A further prospective telephone enquiry of these 18 patients revealed that 15 of 18 patients continued to take cholestyramine (median: 6 years, range: 1-15 years). There were no hospital admissions related to diarrhoea and there was no mortality in this group of patients.

CONCLUSION

The long-term outlook of this group of patients is excellent. We have shown the chronic nature of this condition as evidenced by the continued requirement of cholestyramine.

摘要

背景

感染后胆酸吸收不良包括一组有急性肠胃炎发作史并引发慢性腹泻的患者。我们从病历中回顾性地确定了这些患者,并评估了他们的长期临床病程。

材料和方法

我们检查了 135 名患者的记录,其中 75 名患者的硒-同型胆酸牛磺酸结果小于 10%(1 周保留)。

结果

25 名患者(13 名女性,12 名男性)在经过广泛调查后被确诊为感染后胆酸吸收不良。考来烯胺用于治疗腹泻,腹泻频率从 7.8 次/天降至 1.9 次/天(P=0.001)。考来烯胺的平均剂量从 8.2 克/天降至 5.4 克/天(P=0.005)。25 名患者中的 18 名(72%)通过考来烯胺成功缓解了腹泻,并持续使用至今。门诊随访的中位数时间为 1.58 年(范围:1-5 年)。对这 18 名患者进行进一步的前瞻性电话询问显示,18 名患者中有 15 名(75%)继续服用考来烯胺(中位数:6 年,范围:1-15 年)。没有与腹泻相关的住院治疗,也没有患者死亡。

结论

这群患者的长期预后良好。我们已经证明了这种情况的慢性性质,因为需要持续使用考来烯胺。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验